PRECIGEN, INC. Cost of Services (Deprecated 2018-01-31)
PRECIGEN, INC. (PGEN) reported Cost of Services (Deprecated 2018-01-31) of $7.89 million for the 3-month period ending 2018-06-30, per its 10-Q filed 2018-08-13.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfServices · last filed 2018-08-13
- PRECIGEN, INC. cost of services (deprecated 2018-01-31) for the quarter ending 2018-06-30 was $7.89M, a 1.16% decline year-over-year.
- PRECIGEN, INC. cost of services (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $6.78M, a 0.31% decline year-over-year.
- PRECIGEN, INC. cost of services (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $7.72M, a 26.08% increase year-over-year.
- PRECIGEN, INC. cost of services (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $7.01M, a 20.85% increase year-over-year.
- PRECIGEN, INC. cost of services (deprecated 2018-01-31) for fiscal 2017 was $29.52M, a 23.38% increase from fiscal 2016.
- PRECIGEN, INC. cost of services (deprecated 2018-01-31) for fiscal 2016 was $23.93M, a 3.22% increase from fiscal 2015.
- PRECIGEN, INC. cost of services (deprecated 2018-01-31) for fiscal 2015 was $23.18M, a 181.86% increase from fiscal 2014.
- PRECIGEN, INC. cost of services (deprecated 2018-01-31) for fiscal 2014 was $8.22M.
| Period end | Cost of Services (Deprecated 2018-01-31) 3 month | Cost of Services (Deprecated 2018-01-31) 6 month | Cost of Services (Deprecated 2018-01-31) 9 month | Cost of Services (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-06-30 | $7.89M 10-Q · filed 2018-08-13 | $14.68M 10-Q · filed 2018-08-13 | $22.40M derived: sum of 3 quarters · filed 2018-08-13 | $29.41M derived: sum of 4 quarters · filed 2018-08-13 |
| 2018-03-31 | $6.78M 10-Q/A · filed 2018-08-13 | $14.50M derived: sum of 2 quarters · filed 2018-08-13 | $21.52M derived: sum of 3 quarters · filed 2018-08-13 | $29.50M derived: sum of 4 quarters · filed 2018-08-13 |
| 2017-12-31 | $7.72M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $14.73M derived: sum of 2 quarters · filed 2018-03-01 | $22.72M derived: sum of 3 quarters · filed 2018-08-13 | $29.52M 10-K · filed 2018-03-01 |
| 2017-09-30 | $7.01M 10-Q · filed 2017-11-09 | $15.00M derived: sum of 2 quarters · filed 2018-08-13 | $21.80M 10-Q · filed 2017-11-09 | $27.93M derived: sum of 4 quarters · filed 2018-08-13 |
| 2017-06-30 | $7.99M 10-Q · filed 2018-08-13 | $14.79M 10-Q · filed 2018-08-13 | $20.91M derived: sum of 3 quarters · filed 2018-08-13 | $26.72M derived: sum of 4 quarters · filed 2018-08-13 |
| 2017-03-31 | $6.80M 10-Q/A · filed 2018-08-13 | $12.93M derived: sum of 2 quarters · filed 2018-08-13 | $18.73M derived: sum of 3 quarters · filed 2018-08-13 | $25.06M derived: sum of 4 quarters · filed 2018-08-13 |
| 2016-12-31 | $6.12M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $11.93M derived: sum of 2 quarters · filed 2018-03-01 | $18.26M derived: sum of 3 quarters · filed 2018-03-01 | $23.93M 10-K · filed 2018-03-01 |
| 2016-09-30 | $5.80M 10-Q · filed 2017-11-09 | $12.13M derived: sum of 2 quarters · filed 2017-11-09 | $17.81M 10-Q · filed 2017-11-09 | $23.67M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $6.33M 10-Q · filed 2017-08-09 | $12.00M 10-Q · filed 2017-08-09 | $17.87M derived: sum of 3 quarters · filed 2018-03-01 | $23.32M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $5.67M 10-Q · filed 2017-05-10 | $11.54M derived: sum of 2 quarters · filed 2018-03-01 | $16.99M derived: sum of 3 quarters · filed 2018-03-01 | $23.49M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $5.87M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $11.32M derived: sum of 2 quarters · filed 2018-03-01 | $17.82M derived: sum of 3 quarters · filed 2018-03-01 | $23.18M 10-K · filed 2018-03-01 |
| 2015-09-30 | $5.45M 10-Q · filed 2016-11-09 | $11.95M derived: sum of 2 quarters · filed 2016-11-09 | $17.32M 10-Q · filed 2016-11-09 | $23.23M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $6.50M 10-Q · filed 2016-08-09 | $11.87M 10-Q · filed 2016-08-09 | $17.77M derived: sum of 3 quarters · filed 2017-03-01 | $20.09M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $5.36M 10-Q · filed 2016-05-10 | $11.27M derived: sum of 2 quarters · filed 2017-03-01 | $13.59M derived: sum of 3 quarters · filed 2017-03-01 | $13.59M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $5.91M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $8.22M derived: sum of 2 quarters · filed 2017-03-01 | $8.22M derived: sum of 3 quarters · filed 2017-03-01 | $8.22M 10-K · filed 2017-03-01 |
| 2014-09-30 | $2.32M 10-Q · filed 2015-11-09 | $2.32M derived: sum of 2 quarters · filed 2015-11-09 | $2.32M 10-Q · filed 2015-11-09 | $2.32M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $0.00 10-Q · filed 2015-08-10 | $0.00 10-Q · filed 2015-08-10 | $0.00 derived: sum of 3 quarters · filed 2016-02-29 | $0.00 derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $0.00 10-Q · filed 2015-05-11 | $0.00 derived: sum of 2 quarters · filed 2016-02-29 | $0.00 derived: sum of 3 quarters · filed 2016-02-29 | |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $0.00 derived: sum of 2 quarters · filed 2016-02-29 | $0.00 10-K · filed 2016-02-29 | |
| 2013-09-30 | $0.00 10-Q · filed 2014-11-13 | $0.00 10-Q · filed 2014-11-13 | ||
| 2012-12-31 | $0.00 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |